Table 1B. Dopamine in medication-free schizophrenia patients with a first psychotic episode.
Study | Technique and ligand | Sample size | Main finding |
---|---|---|---|
Abi-Dargham et al.163 | [11C]NNC 112 PET | 16 SCZ of whom 7 FEP 16 HC | D1r bp DLPFC patients>HC |
Abi-Dargham et al.164 | [11C]NNC 112 PET | 30 FEP 15 HC | DAT FEP<HC |
Buchsbaum et al.165 | (18)F-fallypride PET | 15 FEP 15 HC | bp FEP<HC |
Corripio et al.166 | 123I-IBZM SPECT | 18 FEPa 12 HC | D2r bp FEP>HC |
Corripio et al.167 | 123I-IBZM SPECT | 37 FEPa 18 HC | D2r striatal/frontal ratios FEP>HC in those with SCZ |
Glenthoj et al.168 | 123I-IBZM SPECT | 25 FEP 20 HC | Extra striatal D2/D3 DAr bp FEP=HC |
Graff-Guerrerro et al.169 | [(11)C]-(+)-PHNO PET | 13 FEPa 13 HC | Nondisplaceable D2/D3 bp FEP=HC |
Graff-Guerrerro et al.170 | [(11)C]-(+)-PHNO PET | 13 FEPa 13 HC | D2/D3 bp FEP=HC |
Hietala et al.171 | [18F]-DOPA PET | 7 FEP 8 HC | Striatal DA synthesis capacity FEP>HC |
Hietala et al.172 | [18F]-DOPA PET | 10 FEP 10 HC | Striatal DA synthesis capacity FEP>HC |
Hsiao et al.173 | [99mTc]TRODAT SPECT | 12 FEP 12 HC | DAT FEP=HC |
Karlsson et al.174 | [(11)C]SCH 23390 PET | 10 FEP 10 HC | D1r bp FEP=HC |
Laakso et al.175 | [18F]CFT PET | 9 FEP 9 HC | DAT FEP=HC |
Lavalaye et al.176 | [123I]FP-CIT SPECT | 36 SCZ of whom 10 FEP 10 HC | DAT FEP=HC |
Lehrer et al.177 | (18)F-fallypride PET | 33 SCZ of whom 14 FEP 18 HC | bp medial thalamus SCZ<HC (ES=0.89) |
Lindstrom et al.178 | [11C]-DOPA PET | 12 SCZ of whom 10 FEP 10 HC | Striatal DA synthesis capacity FEP>HC |
Mateos et al.179 | [123I]FP-CIT SPECT | 20 FEP 10 HC | DAT FEP<HC |
Mateos et al.180 | [123I]FP-CIT SPECT | 30 FEP 15 HC | DAT FEP<HC |
Mateos et al.181 | [123I]FP-CIT SPECT | 20 FEP 15 HC | DAT FEP<HC |
Nozaki et al.182 | [11C]-DOPA PET | 18 SCZ of whom 14 FEP 10 HC | bp FEP>HC |
Safont et al.183 | (123)I-IBZM SPECT | 37 FEPa 18 HC | D2r bp cannabis users=non-users |
Schmitt et al.184 | ([99mTc]TRODAT-1 SPECT | 10 FEP 10 HC | DAT FEP=HC |
Schmitt et al.185 | ([99mTc]TRODAT-1 SPECT | 28 FEP 12 HC | DAT FEP=HC |
Schmitt et al.186 | [99mTc]TRODAT-1 and [123I]IBZM SPECT | 20 FEP 12 HC | DAT FEP=HC D2r bp FEP=HC |
Schmitt et al.187 | 123I-IBZM SPECT | 23 FEP 10 HC | D2r bp FEP<HC |
Schmitt et al.188 | [99mTc]TRODAT-1 and [123I]IBZM SPECT | 12 FEP 12 HC | DAT FEP>HC D2r bp FEP=HC |
Talvik et al.189 | [11C]FLB 457 PET | 9 FEP 8 HC | D2/D3 bp right thalamus FEP<HC, |
Talvik et al.190 | [(11)C]raclopride PET | 18 FEP 17 HC | D2 bp right thalamus FEP<HC, |
Yang et al.191 | [99mTc]TRODAT SPECTand ([(123)I]IBZM) SPECT | 11 FEP 12 HC | DAT FEP=HC D2/D3 bp FEP=HC |
Yasuno et al.192 | [(11)C]FLB 457 PET | 10 FEP 19 HC | D2 bp FEP<HC thalamus |
Abbreviations: bp, binding potential; D1r, dopamine D1 receptor; D2r, dopamine D2 receptor; DAT, striatal dopamine transporter; ES, effect size; FEP, first-episode psychosis; PET, positron emission tomography; SCZ, schizophrenia.
Samples overlap.